INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $32,394,000 | -21.8% | 781,325 | -9.6% | 1.84% | -28.9% |
| Q2 2020 | $41,411,000 | -39.0% | 864,345 | -19.8% | 2.58% | -67.5% |
| Q1 2020 | $67,889,000 | -55.1% | 1,078,291 | -11.6% | 7.95% | -22.6% |
| Q4 2019 | $151,073,000 | +94.4% | 1,219,121 | +4.1% | 10.27% | +53.3% |
| Q3 2019 | $77,702,000 | -4.9% | 1,170,910 | +14.1% | 6.70% | -6.5% |
| Q2 2019 | $81,670,000 | +10.3% | 1,026,388 | +55.0% | 7.17% | +28.9% |
| Q1 2019 | $74,074,000 | -9.6% | 662,200 | -32.2% | 5.56% | -1.6% |
| Q2 2018 | $81,907,000 | +15.6% | 976,127 | -15.3% | 5.65% | +4.6% |
| Q1 2018 | $70,873,000 | +25.0% | 1,152,032 | +18.7% | 5.40% | +35.0% |
| Q4 2017 | $56,721,000 | +67.4% | 970,926 | +66.3% | 4.00% | +79.1% |
| Q3 2017 | $33,883,000 | – | 583,790 | – | 2.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |